Clinical trial
Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
NCT02526160 · Kyowa Kirin, Inc., Industry · Completed
Key facts
| NCT number | NCT02526160 |
|---|---|
| Title | Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH) |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults With X-linked Hypophosphatemia (XLH) |
| Lead sponsor | Kyowa Kirin, Inc., Industry |
| Collaborators | Kyowa Kirin Co., Ltd. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | X-linked Hypophosphatemia |
| Intervention type | Biological, Other |
| Interventions | burosumab, Placebo |
| Enrollment | 134 |
| Start date | Oct 22, 2015 |
| Primary completion | Dec 22, 2016 |
| Completion | Dec 6, 2018 |
| First posted | Aug 18, 2015 |
| Last update posted | Jun 18, 2024 |
| Countries | France, Ireland, Italy, Japan, South Korea, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: